$VMD

Smokoff Timothy sold $230K of VMD

Smokoff Timothy sold 20,000 shares of VIEMED HEALTHCARE, INC. (VMD) at an average of $11.50 ($11.41–$11.56, $0.23M total) across 5 trades on 2026-06-24.

Original reporting
SEC EDGAR · Smokoff Timothy
Published Jun 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VMD
Neutral
medium confidence
Mentioned
$VMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VMDNeutralLow
01

Why it matters

A director’s open-market sale of 20,000 shares at roughly $11.50 each is disclosed, totaling about $229,967, with holdings after the sale of 75,518 shares.

02

Market read

Traders may monitor VMD for any clustering of insider selling or changes in trading behavior, but there is no fundamental catalyst in the text.

03

What to watch

The article does not provide context on total holdings, prior sale cadence, or whether other insiders sold around the same time, which limits inference from a single transaction.

Relevance 4/10Novelty 3/10Timing: Filed 2026-06-26, reporting sales executed 2026-06-24.

Background

The article is a SEC Form 4 insider transaction disclosure for VIEMED HEALTHCARE, Inc. (VMD).

Company-level read

Ticker impact

$VMDNeutralMedium confidence
Context

VIEMED HEALTHCARE director Smokoff Timothy sold about $229,967 of VMD shares in open-market transactions at $11.41 to $11.56.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or unusual volume around the sale window.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan stated and no accompanying company-specific news (earnings, guidance, deals, or regulatory actions).

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • VIEMED HEALTHCARE, INC.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Smokoff Timothy

    Director who sold 20,000 shares across five trades on 2026-06-24.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

$VMDMedAI 8/10

Viemed (VMD) Q2 2026 Earnings Call Transcript

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

$VMDMedAI 8/10

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.